NERV Minerva Neurosciences, Inc.: שווי החברה בספרים

The price evolution of Minerva Neurosciences (NERV) on the GURU.Markets platform is currently at -0.21. The business minimizes supplier dependency risks by distributing neurobiological tests across various laboratories. The development strategy relies on bringing roluperidone to market for schizophrenia therapy via FDA approval. Meanwhile, the management model is based on the full delegation of production and trials to external partners to maintain flexibility.

Professional managers utilize fundamental filters to assess the real value of net assets, determining the capital margin of safety relative to market quotes. In the case of Minerva Neurosciences (NERV), where a lack of revenue makes the company dependent on cash reserves to cover back-office expenses, the dynamics of the company's book capitalization clearly demonstrate the burn rate during the period of awaiting regulatory approvals.